ArticleHuman vaccines & immunotherapeutics2024
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study.
Jassada Buaboonnam et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.